Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow

Details

Serval ID
serval:BIB_AB9477ADBCAE
Type
Article: article from journal or magazin.
Collection
Publications
Institution
Title
Standardization of the immunocytochemical detection of neuroblastoma cells in bone marrow
Journal
Journal of Histochemistry and Cytochemistry
Author(s)
Swerts  K., Ambros  P. F., Brouzes  C., Navarro  J. M., Gross  N., Rampling  D., Schumacher-Kuckelkorn  R., Sementa  A. R., Ladenstein  R., Beiske  K.
ISSN
0022-1554
Publication state
Published
Issued date
12/2005
Peer-reviewed
Oui
Volume
53
Number
12
Pages
1433-40
Notes
Journal Article
Research Support, Non-U.S. Gov't --- Old month value: Dec
Abstract
Standard cytomorphological examination of bone marrow (BM) aspirates does not appear to be sensitive enough to detect single neuroblastoma cells. The SIOPEN Neuroblastoma Bone Marrow Committee developed a sensitive and reproducible anti-GD2 immunocytochemical assay and introduced morphological and immunocytological criteria for the interpretation of results. Fixed cytospins were incubated with a commercially available anti-GD2 monoclonal antibody and an APAAP kit. Cells fulfilling all morphological and immunocytological criteria were called criteria-positive cells (CPCs). Not convincingly interpretable cells fulfilled some, but not all, criteria, and negative cells displayed only exclusion criteria. The genetic profile of doubtful cells was checked by fluorescence in situ hybridization. Ideally, 3 x 10(6) cells were analyzed to reach a 95% probability of detecting one tumor cell in 1 x 10(6) mononuclear cells. Four quality control rounds were organized to validate the method. A total of 111 quality control samples were analyzed. Two main improvements were achieved: in discordant cases, the range between the lowest and highest reported result was reduced by half, and discordant results were only found in samples with less than 10 CPCs per 1 x 10(6). This article describes the first internationally standardized protocol to detect and quantify rare neuroblastoma cells by immunocytochemistry. This method is an indispensable tool for multicenter studies evaluating the clinical significance of minimal residual disease in neuroblastoma.
Keywords
Bone Marrow/*pathology Bone Marrow Cells/pathology Cell Line False Positive Reactions Humans Immunohistochemistry/*standards In Situ Hybridization, Fluorescence/standards Neoplasm, Residual Neuroblastoma/*pathology Quality Control Sensitivity and Specificity
Pubmed
Web of science
Open Access
Yes
Create date
20/01/2008 15:55
Last modification date
20/08/2019 15:15
Usage data